---
title: "Key facts: Kymera (KYMR) Q2 $65M; $1.5B cash; KT-621 data end-2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295069217.md"
description: "Kymera (KYMR) Q2 2026: collaboration revenue $65M (Gilead $45M option fee, Sanofi $20M milestone); R&D $119.5M; G&A $21.1M; net loss $61.2M; cash $1.5B, runway into 2029 2 sourcesKymera Therapeutics (KYMR) expects KT-621 Phase 2b Alzheimer's topline data by year-end 2026 and plans to start Phase 3 trials by mid-2027. ReutersDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources."
datetime: "2026-08-06T07:15:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295069217.md)
  - [en](https://longbridge.com/en/news/295069217.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295069217.md)
generator: "portal-rs"
---

# Key facts: Kymera (KYMR) Q2 $65M; $1.5B cash; KT-621 data end-2026

-   Kymera (KYMR) Q2 2026: collaboration revenue $65M (Gilead $45M option fee, Sanofi $20M milestone); R&D $119.5M; G&A $21.1M; net loss $61.2M; cash $1.5B, runway into 2029 2 sources
-   Kymera Therapeutics (KYMR) expects KT-621 Phase 2b Alzheimer's topline data by year-end 2026 and plans to start Phase 3 trials by mid-2027. Reuters

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [KYMR.US](https://longbridge.com/en/quote/KYMR.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [California State Teachers Retirement System Raises Stock Position in Kymera Therapeutics, Inc. $KYMR](https://longbridge.com/en/news/298880254.md)
- [Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth](https://longbridge.com/en/news/298621247.md)
- [Gilead launches research facility in US for new medicine development](https://longbridge.com/en/news/298441968.md)
- [RXRX: AI-driven drug discovery platform delivers first-in-class assets and major partnership milestones](https://longbridge.com/en/news/299064447.md)
- [KYMR: Oral immunology therapies targeting STAT6 and IRF5 advance toward key data readouts this year](https://longbridge.com/en/news/298625731.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**